Darifenacin

Darifenacin

File:Darifenacin.svg
Clinical data
Pregnancy category	AU: B3 US: C (Risk not ruled out)
Routes of administration	Oral
ATC code	G04BD10 (WHO)
Legal status
Legal status	US: ℞-only
Pharmacokinetic data
Bioavailability	15 to 19% (dose-dependent)
Protein binding	98%
Metabolism	Hepatic (CYP2D6- and CYP3A4-mediated)
Elimination half-life	13 to 19 hours
Excretion	Renal (60%) and biliary (40%)
Identifiers
IUPAC name 2-[1-[2-(2,3-dihydrobenzofuran-5-yl)ethyl] pyrrolidin-3-yl] -2,2-diphenyl-acetamide
CAS Number	133099-04-4
PubChem CID	444031
DrugBank	APRD00903
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C28H30N2O2
Molar mass	426.55 g/mol

WikiDoc Resources for Darifenacin
Articles
Most recent articles on Darifenacin Most cited articles on Darifenacin Review articles on Darifenacin Articles on Darifenacin in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Darifenacin Images of Darifenacin Photos of Darifenacin Podcasts & MP3s on Darifenacin Videos on Darifenacin
Evidence Based Medicine
Cochrane Collaboration on Darifenacin Bandolier on Darifenacin TRIP on Darifenacin
Clinical Trials
Ongoing Trials on Darifenacin at Clinical Trials.gov Trial results on Darifenacin Clinical Trials on Darifenacin at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Darifenacin NICE Guidance on Darifenacin NHS PRODIGY Guidance FDA on Darifenacin CDC on Darifenacin
Books
Books on Darifenacin
News
Darifenacin in the news Be alerted to news on Darifenacin News trends on Darifenacin
Commentary
Blogs on Darifenacin
Definitions
Definitions of Darifenacin
Patient Resources / Community
Patient resources on Darifenacin Discussion groups on Darifenacin Patient Handouts on Darifenacin Directions to Hospitals Treating Darifenacin Risk calculators and risk factors for Darifenacin
Healthcare Provider Resources
Symptoms of Darifenacin Causes & Risk Factors for Darifenacin Diagnostic studies for Darifenacin Treatment of Darifenacin
Continuing Medical Education (CME)
CME Programs on Darifenacin
International
Darifenacin en Espanol Darifenacin en Francais
Business
Darifenacin in the Marketplace Patents on Darifenacin
Experimental / Informatics
List of terms related to Darifenacin

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Darifenacin (Enablex®, Novartis) is a medication used to treat urinary incontinence.

Darifenacin works by blocking the M3 muscarinic acetylcholine receptor, which is primarily responsible for bladder muscle contractions. It thereby decreases the urgency to urinate. It should not be used in people with urinary retention.

It is not known whether this selectivity for the M3 receptor translates into any clinical advantage when treating symptoms of overactive bladder syndrome.(1)

Administration

Darifenacin is administered as a once-daily extended-release oral tablet.

References

(1) SPC for emselex-revised on 29/11/06 (available at www.medicines.org.uk)